GLTO - Galecto Inc Stock Price, Fair Value and News

0.72USD+0.04 (+5.88%)Market Closed

Market Summary

USD0.72+0.04

Market Closed

5.88%

GLTO Stock Price

View Fullscreen

GLTO RSI Chart

GLTO Valuation

Market Cap

19.3M

Price/Earnings (Trailing)

-0.62

Price/Free Cashflow

-0.57

GLTO Price/Earnings (Trailing)

GLTO Profitability

Return on Equity

-109.49%

Return on Assets

-94.93%

Free Cashflow Yield

-175.08%

GLTO Fundamentals

GLTO Earnings

Earnings (TTM)

-30.8M

Earnings Growth (Yr)

57.85%

Earnings Growth (Qtr)

15.41%

Breaking Down GLTO Revenue

Last 7 days

6.0%

Last 30 days

-6.6%

Last 90 days

14.5%

Trailing 12 Months

-59.2%

How does GLTO drawdown profile look like?

GLTO Financial Health

Current Ratio

7.07

GLTO Investor Care

Shares Dilution (1Y)

5.61%

Diluted EPS (TTM)

-1.14

Tracking the Latest Insider Buys and Sells of Galecto Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 15, 2023	orbimed advisors llc	sold	-617,010	0.75	-822,680	-
Jul 31, 2023	orbimed advisors llc	sold	-628,200	3.00	-209,400	-
Jul 25, 2023	orbimed advisors llc	sold	-114,464	2.92	-39,200	-
Jul 13, 2023	orbimed advisors llc	sold	-467,280	2.4	-194,700	-
Apr 17, 2023	orbimed advisors llc	sold	-25,785	1.97	-13,089	-
Apr 14, 2023	orbimed advisors llc	sold	-77,089	1.86	-41,446	-
Apr 13, 2023	orbimed advisors llc	sold	-25,381	1.82	-13,946	-
Apr 12, 2023	orbimed advisors llc	sold	-4,277	1.81	-2,363	-
Apr 11, 2023	orbimed advisors llc	sold	-25,381	1.82	-13,946	-
Apr 10, 2023	orbimed advisors llc	sold	-91,698	1.79	-51,228	-

Which funds bought or sold GLTO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	added	31.84	6,000	18,000	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	592	-	-	-%
Apr 24, 2024	Spire Wealth Management	unchanged	-	240	1,560	-%
Apr 23, 2024	Summit Trail Advisors, LLC	new	-	19,500	19,500	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.79	2,916	159,264	-%
Feb 14, 2024	Novo Holdings A/S	unchanged	-	-	1,798,410	0.11%
Feb 14, 2024	STATE STREET CORP	unchanged	-	22.00	32,332	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-7.89	-1,841	21,889	-%
Feb 14, 2024	Soleus Capital Management, L.P.	sold off	-100	-645,864	-	-%

Are Funds Buying or Selling GLTO?

Are funds buying GLTO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GLTO

No. of Funds

Unveiling Galecto Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Oct 03, 2023	otto erik	6.7%	1,800,000	SC 13G
Sep 18, 2023	orbimed advisors llc	2.8%	749,557	SC 13D/A
Sep 05, 2023	orbimed advisors llc	4.2%	1,149,694	SC 13D/A
Aug 17, 2023	orbimed advisors llc	5.9%	1,607,579	SC 13D/A
Aug 02, 2023	orbimed advisors llc	8.3%	2,241,440	SC 13D/A
Jul 17, 2023	orbimed advisors llc	9.6%	2,455,640	SC 13D/A
Apr 07, 2023	orbimed advisors llc	10.5%	2,696,654	SC 13D/A
Feb 14, 2022	cormorant asset management, lp	0%	0	SC 13G/A
Feb 11, 2022	hbm healthcare investments (cayman) ltd.	0%	0	SC 13G/A
Feb 16, 2021	cormorant asset management, lp	4.27%	1,078,832	SC 13G/A

Recent SEC filings of Galecto Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	10-Q	Quarterly Report
Apr 16, 2024	PRE 14A	PRE 14A
Mar 26, 2024	8-K	Current Report
Mar 08, 2024	S-8	Employee Benefits Plan
Mar 08, 2024	10-K	Annual Report
Feb 09, 2024	SCHEDULE 13G/A	SCHEDULE 13G/A

Peers (Alternatives to Galecto Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Galecto Inc News

Latest updates

Galecto Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-15.0%	32.00	38.00	50.00	59.00	65.00	73.00	82.00	93.00	109	122	136	147	159	172	98.00	57.00
Current Assets	-17.0%	31.00	37.00	47.00	55.00	57.00	64.00	71.00	82.00	97.00	110	107	108	117	169	96.00	56.00
Cash Equivalents	-1.7%	21.00	21.00	23.00	23.00	25.00	33.00	28.00	30.00	45.00	63.00	66.00	69.00	74.00	164	85.00	12.00
Net PPE	-6.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Liabilities	-26.8%	4.00	6.00	13.00	15.00	14.00	11.00	9.00	8.00	8.00	5.00	6.00	5.00	6.00	6.00	9.00	8.00
Current Liabilities	-25.6%	4.00	6.00	13.00	15.00	14.00	11.00	9.00	7.00	7.00	5.00	6.00	5.00	6.00	6.00	8.00	8.00
Shareholder's Equity	-12.9%	28.00	32.00	37.00	44.00	50.00	62.00	73.00	85.00	101	117	130	141	153	165	-	-
Retained Earnings	-2.1%	-261	-256	-249	-241	-230	-217	-203	-189	-173	-156	-142	-130	-117	-104	-92.78	-69.52
Additional Paid-In Capital	0.5%	289	288	287	285	281	280	278	277	275	274	272	271	270	269	1.00	1.00
Shares Outstanding	0%	27.00	27.00	27.00	27.00	26.00	26.00	25.00	25.00	25.00	25.00	25.00	25.00	-	-	-	-
Float	-	-	-	-	59.00	-	38.00	-	-	-	-	-	89.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	48.2%	-5,936	-11,463	-8,454	-7,849	-9,134	-11,448	-9,847	-14,840	-6,797	-17,829	-9,159	-11,169	-14,151	-14,517	-8,577	-7,131	-7,978	-	-
Share Based Compensation	24.7%	1,359	1,090	1,464	1,439	1,434	1,349	1,399	1,419	1,404	1,243	1,219	987	1,031	-	-	-	-	-	-
Cashflow From Investing	-41.0%	5,650	9,580	8,285	3,091	1,374	14,330	8,312	-51.00	-10,207	14,412	7,047	5,124	-74,631	-	-	-	-	-	-
Cashflow From Financing	-	-	-	171	2,682	23.00	65.00	424	-	-	-	-	-	-	91,790	55,930	1.00	39,668	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GLTO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 2,463	$ 10,362
General and administrative	3,278	3,130
Total operating expenses	5,741	13,492
Loss from operations	(5,741)	(13,492)
Other income, net
Interest income, net	257	434
Foreign exchange transaction gain, net	7	64
Total other income, net	264	498
Net loss	$ (5,477)	$ (12,994)
Net loss per common share, basic	$ (0.2)	$ (0.51)
Net loss per common share, diluted	$ (0.2)	$ (0.51)
Weighted-average number of shares used in computing net loss per common share, basic	27,112,697	25,672,902
Weighted-average number of shares used in computing net loss per common share, diluted	27,112,697	25,672,902
Other comprehensive loss, net of tax
Currency translation gain (loss)	$ (86)	$ 25
Unrealized gain on marketable securities	32	92
Other comprehensive gain (loss), net of tax	(54)	117
Total comprehensive loss	$ (5,531)	$ (12,877)

GLTO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 21,091	$ 21,465
Marketable securities	6,080	11,686
Prepaid expenses and other current assets	3,370	3,623
Total current assets	30,541	36,774
Operating lease right-of-use asset	152	247
Equipment, net	73	78
Other assets, non-current	1,711	1,128
Total assets	32,477	38,227
Current liabilities
Accounts payable	1,665	1,702
Accrued expenses and other current liabilities	2,653	4,128
Total current liabilities	4,318	5,830
Operating lease liabilities, non-current		66
Total liabilities	4,318	5,896
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023
Common stock, par value of $0.00001 per share; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 27,112,697 shares issued and outstanding at March 31, 2024 and December 31, 2023
Additional paid-in capital	289,395	288,036
Accumulated deficit	(261,562)	(256,085)
Accumulated other comprehensive gain	326	380
Total stockholders’ equity	28,159	32,331
Total liabilities and stockholders' equity	$ 32,477	$ 38,227

About Galecto Inc

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

CEO	Dr. Hans T. Schambye M.D., Ph.D.
WEBSITE	https://galecto.com
INDUSTRY	Biotechnology
EMPLOYEES	45

Galecto Inc Frequently Asked Questions

What is the ticker symbol for Galecto Inc? What does GLTO stand for in stocks?

GLTO is the stock ticker symbol of Galecto Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Galecto Inc (GLTO)?

As of Thu May 02 2024, market cap of Galecto Inc is 19.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GLTO stock?

You can check GLTO's fair value in chart for subscribers.

What is the fair value of GLTO stock?

You can check GLTO's fair value in chart for subscribers. The fair value of Galecto Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Galecto Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GLTO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Galecto Inc a good stock to buy?

The fair value guage provides a quick view whether GLTO is over valued or under valued. Whether Galecto Inc is cheap or expensive depends on the assumptions which impact Galecto Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLTO.